Immunology

The Immunology Department at St James’s hospital  runs a number of both investigator-led and industry centered drug trials in Immunology.

Current Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
HAE Survey Burden of hereditary angioedema (HAE) and impact on quality of life: A multi-national survey of patients and caregiversObservational-non invasive Takeda Commercial: Industry
Intercept A Phase 2, Double- Blind Randomized, Parallel- Group Study Evaluating the Efficacy, Safety and Tolerability of Obeticholic Acid, Administrated Alone or in Combination with Bezafibrate, in subjests with Primary Biliary Cholangitis who had an Inadequate Response or who were Unable to Tolerate Ursodeoxycholic Acid Clinical trial NCT04594694)Intercept Pharmaceutials Commercial: Industry
HyQviaNon-interventional Post-Authorization Safety Study on the Long-Term Safety of HyQvia in Subjects treated with HyQviaObservational-non invasive (NCT01034969)BaxaltaCommercial: Industry
IOS registryIcatibant Outcome Survey (IOS) registry protocolObservational-non invasive (NCT01034969)ShireCommercial: Industry
ABT in UrticariaHealth through attention based training (ABT) for patients in SJH with urticariaObservational-non invasiveNon-commercial: Academic
SOLAR study A Phase IIIb, Randomized, Multicenter, Active-controlled,Parallelgroup, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alfenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed Clinical trial ViiV Healthcare Commercial: Industry
Santorini Treatment of High and Very high riSk dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events in Europe – a MultInatioNal ObservatIonal Study (SANTORINI) Observational-non invasive Daiichi Sankyo Europe GmbH Commercial: Industry
Past Trials & Studies
Study NameStudy TitleStudy TypeSponsorSponsor Type
CDZ OLEAn open-label, non-randomized extension study to evaluate the long term safety, tolerability, efficacy and pharmacokinetics of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical Trial (NCT02859727)(2016-000468-41)NovartisCommercial: Industry
CDZAn open-label, non-randomized, within-patient dose-finding study followed by a randomized, subject, investigator and sponsor-blinded placebo controlled study to assess the efficacy and safety of CDZ173 in patients with APDS/PASLI (Activated phosphoinositide 3-kinase delta syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency)Clinical Trial (NCT02435173) (2014-003876-22)NovartisCommercial: Industry